NHL

Evolv Technology® Named Official Fan Screening Provider of Bridgestone Arena

Retrieved on: 
Wednesday, January 11, 2023

Evolv Technology (NASDAQ: EVLV), the leader in AI-based weapons detection security screening, today announced its partnership with Nashville, Tennessee’s iconic Bridgestone Arena .

Key Points: 
  • Evolv Technology (NASDAQ: EVLV), the leader in AI-based weapons detection security screening, today announced its partnership with Nashville, Tennessee’s iconic Bridgestone Arena .
  • Located in the heart of Music City, Bridgestone Arena is home to the NHL’s Nashville Predators and numerous national and international events including the annual Country Music Association (CMA) Awards.
  • Additionally, Bridgestone Arena is eighth in the world on Billboard’s 2022 Year-in-Touring bulletin Top Venues (15,001+ capacity) chart with $94.1 million and 800,000 tickets sold.
  • By enabling Evolv Express, the Titans caught 254 prohibited items in just a three-game period and doubled fan satisfaction scores .

Cadmatic is Part of Consortium Leading EU-Funded SEUS Project for Smarter and More Productive Shipbuilding

Retrieved on: 
Thursday, January 12, 2023

Cadmatic is part of a consortium of industrial companies and academic institutions that is leading the EU-funded Smart European Shipbuilding project (SEUS) that was launched 1 January 2023.

Key Points: 
  • Cadmatic is part of a consortium of industrial companies and academic institutions that is leading the EU-funded Smart European Shipbuilding project (SEUS) that was launched 1 January 2023.
  • View the full release here: https://www.businesswire.com/news/home/20230111005065/en/
    Cadmatic is Part of Consortium Leading EU-Funded SEUS Project for Smarter and More Productive Shipbuilding (Photo: Business Wire)
    The platform solution aims to slash the time needed for ship engineering by 30% and cut assembly times by an ambitious 20%.
  • Cadmatic is responsible for leading the technical coordination of the four-year-long SEUS project.
  • “We are proud to be leading the technical coordination and working alongside the other consortium partners on this ambitious project.

Future Continues to Strengthen U.S. Sales Leadership With New Hires

Retrieved on: 
Monday, January 9, 2023

NEW YORK, Jan. 09, 2023 (GLOBE NEWSWIRE) -- Digital powerhouse, Future Publishing , has today announced the appointment of two senior Sales hires to support its accelerated growth.

Key Points: 
  • NEW YORK, Jan. 09, 2023 (GLOBE NEWSWIRE) -- Digital powerhouse, Future Publishing , has today announced the appointment of two senior Sales hires to support its accelerated growth.
  • Prior to joining Future, Ali Dib was the Global Agency Partnerships Director at The Washington Post.
  • Zack Sullivan, Chief Revenue Officer of Future, said: “We are thrilled to have Ali and Jeffrey join the Future team based out of our New York office.
  • With Rob George, VP of eCommerce, joining Future at the end of January to lead all eCommerce efforts globally for Future.

C4 Therapeutics Announces 2023 Strategic Priorities to Advance Portfolio of Targeted Protein Degradation Medicines

Retrieved on: 
Monday, January 9, 2023

WATERTOWN, Mass., Jan. 09, 2023 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science to develop a new generation of small-molecule medicines and transform how disease is treated, today announced 2023 strategic priorities to advance its portfolio of targeted protein degradation medicines.

Key Points: 
  • “Based on these achievements, 2023 will be an important year with clinical data expected from our two lead programs, CFT7455 and CFT8634.
  • Present Phase 1 dose escalation data from the ongoing Phase 1/2 trial of CFT7455 in MM in the second half of 2023.
  • Present Phase 1 dose escalation data from the ongoing CFT8634 Phase 1/2 trial in the second half of 2023.
  • A live webcast will be available under “Events & Presentations” in the Investors section of the company’s website at www.c4therapeutics.com .

Precision BioSciences Recaps 2022 Accomplishments and Outlines 2023 Corporate Priorities and Planned Portfolio Milestones

Retrieved on: 
Monday, January 9, 2023

Precision BioSciences (Nasdaq: DTIL), a clinical stage gene editing company developing ARCUS®-based ex vivo allogeneic CAR T and in vivo gene editing therapies, today reported on its significant accomplishments in 2022 and announced its corporate priorities and anticipated clinical development and research milestones for 2023.

Key Points: 
  • Precision BioSciences (Nasdaq: DTIL), a clinical stage gene editing company developing ARCUS®-based ex vivo allogeneic CAR T and in vivo gene editing therapies, today reported on its significant accomplishments in 2022 and announced its corporate priorities and anticipated clinical development and research milestones for 2023.
  • “In 2022, we advanced our corporate priorities strengthening the company and made significant progress with our clinical programs and research pipeline.
  • Progress azer-cel to decision point for Phase 2 trial in non-Hodgkin lymphoma (NHL) subjects who have relapsed following autologous CAR T treatment.
  • Present CAR T clinical update in the first quarter of 2023, based on patient accrual and follow-up.

BioSteel Cements Its Position as Sports Hydration Drink of the Ice and Becomes Official Sports Hydration Partner of Six National Hockey League Franchises

Retrieved on: 
Wednesday, January 11, 2023

Activations include BioSteel trigger promotions and point-of-sale displays at local retailers, sampling opportunities, in-arena branding, social media promotions and more.

Key Points: 
  • Activations include BioSteel trigger promotions and point-of-sale displays at local retailers, sampling opportunities, in-arena branding, social media promotions and more.
  • Earlier this year, BioSteel became the Official Hydration Partner of the NHL and the National Hockey League Players' Association (NHLPA) in a full circle moment for a brand born in an NHL locker room.
  • "We're thrilled to work with BioSteel as the Official Hydration Partner of the Anaheim Ducks.
  • "We're thrilled to welcome BioSteel as our official hydration partner," said Jaime Faulkner, President of Business Operations at the Chicago Blackhawks.

SinoMab Awarded the "Most Valuable Pharmaceutical and Medical Company" in the Selection of the "7th Hong Kong Golden Stocks Awards"

Retrieved on: 
Monday, December 19, 2022

SinoMab was awarded the "Most Valuable Pharmaceutical and Medical Company", highlighting the attention and recognition of the industry and investors on the Company's value and innovation capabilities, which is a great encouragement and even a spur to SinoMab.

Key Points: 
  • SinoMab was awarded the "Most Valuable Pharmaceutical and Medical Company", highlighting the attention and recognition of the industry and investors on the Company's value and innovation capabilities, which is a great encouragement and even a spur to SinoMab.
  • SinoMab is the first Hong Kong-based listed biopharmaceutical company dedicated to the research, development, manufacturing and commercialization of therapeutics, primarily monoclonal antibody ("mAb")-based biologics, for the treatment of immunological diseases.
  • Currently, various candidate products for all-field indications of autoimmune diseases in SinoMab's layout have started clinical trials successively and are progressing steadily.
  • Previously, SinoMab appointed Mr. Shanchun WANG as the President (China) of the Company, mainly responsible for the China operation.

Fate Therapeutics Announces Termination of Collaboration Agreement with Janssen, Pipeline Prioritization, Next-Generation Programs, and Key 2023 Initiatives

Retrieved on: 
Thursday, January 5, 2023

In addition, we look forward this year to the further emergence of our iPSC-derived CAR T-cell programs for the treatment of hematologic malignancies and solid tumors.

Key Points: 
  • In addition, we look forward this year to the further emergence of our iPSC-derived CAR T-cell programs for the treatment of hematologic malignancies and solid tumors.
  • Ongoing Phase 1 Study of FT576 BCMA-targeted CAR NK Cell Program to Accrue Higher-dose, Multi-dose Treatment Cohorts.
  • The Company ended the fourth quarter of 2022 with unaudited cash, cash equivalents, and receivables totaling approximately $475 million.
  • Based on its current operating plan, the Company expects to have sufficient financial resources to fund operations through 2025.

DraftKings Set to Launch Top-Rated Online Sportsbook in Ohio on New Year’s Day

Retrieved on: 
Friday, December 30, 2022

BOSTON, Dec. 30, 2022 (GLOBE NEWSWIRE) -- DraftKings Inc. (Nasdaq: DKNG) announced today plans to launch its award-winning online sportsbook in Ohio on January 1, 2023, pending licensure and regulatory approvals.

Key Points: 
  • BOSTON, Dec. 30, 2022 (GLOBE NEWSWIRE) -- DraftKings Inc. (Nasdaq: DKNG) announced today plans to launch its award-winning online sportsbook in Ohio on January 1, 2023, pending licensure and regulatory approvals.
  • “We’re excited to ring in the New Year with the launch of our top-rated DraftKings Sportsbook app in Ohio,” said Matt Kalish, DraftKings Co-Founder and President, DraftKings North America.
  • DraftKings is committed to creating inclusive and responsible pathways for people to build, create, imagine, and innovate through the DraftKings S.E.R.V.E.S.
  • Eligible customers in Ohio can access the latest betting markets and more by downloading the DraftKings Sportsbook app available via iOS and Android here .

Precision BioSciences Receives Favorable Type C Feedback from the FDA on the Company’s Chemistry, Manufacturing, and Controls (CMC) Strategies for Late-Stage Development of Azercabtagene Zapreleucel, its Lead Allogeneic CAR T Clinical Candidate

Retrieved on: 
Friday, January 6, 2023

Azer-cel is Precision BioSciences lead allogeneic CAR T candidate being evaluated for relapsed or refractory (R/R) non-Hodgkin lymphoma (NHL) in subjects who have relapsed following autologous CAR T treatment.

Key Points: 
  • Azer-cel is Precision BioSciences lead allogeneic CAR T candidate being evaluated for relapsed or refractory (R/R) non-Hodgkin lymphoma (NHL) in subjects who have relapsed following autologous CAR T treatment.
  • “We are pleased with the FDA feedback on key components of our planned CMC package to support azer-cel ongoing development.
  • “There are currently no FDA-approved allogeneic CAR T products to address the high unmet need of the CAR T relapsed or refractory patient population.
  • An effective off-the-shelf allogeneic CAR T treatment has the potential to offer clinical benefit to this growing population of lymphoma patients.”